In conclusion, our results suggest that using the α7nAchR agonist PNU-282987 to activate the CAP can reduce psoriasis-like skin lesions, which is likely mediated by its anti-proliferation and anti-inflammation effects. The gene discussed is CHRNA7; the disease is psoriasis.